- $183.77m
- $58.47m
- $72.76m
Brief: Compugen Presents New Research Data Further Supporting PVRIG As A Potentially Promising Target For Cancer Immunotherapy
U.S. RESEARCH ROUNDUP-Albemarle, Revolve Group, Wabtec
Brief: Compugen Ltd Says USPTO Granted A New Patent Covering Composition Of Matter Of COM902
Brief: Compugen Ltd Files For Mixed Shelf Of Up To $350 Million
Brief: Compugen Reports Q2 Loss Per Share $0.08
Brief: Compugen Reports FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701
Brief: Compugen Doses First Patient In Com701 Phase 1 Monotherapy Expansion Cohort
Brief: Compugen Reports Q1 Loss Per Share $0.10
Compugen sees "encouraging signals" from early-stage cancer trial
Brief: Compugen Presents Data Update From Ongoing Phase 1 Trial Of Com701 At The 2020 AACR Virtual Annual Meeting
Compugen: Rises as co gets new patent for cancer treatment in Europe
Brief: Compugen Expands Intellectual Property Portfolio For Com701 With New European Composition Of Matter Patent
Brief: Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting
Brief: Compugen Announces First Patient Dosed In Com902 Phase 1 Trial For Patients With Advanced Malignancies
Compugen drops on deep-discounted, upsized stock deal
NASDAQ RESUMED AT 08:35 AM
NASDAQ RESUMED AT 08:15 AM
Compugen prices upsized $75 mln stock offering
NASDAQ TRADE HALT MARKET WIDE CIRCUIT BREAKER RESUMPTION AT 08:49 AM